FOXO1 and coronary artery disorder: Power analyses suggest that a sample of >900 TOF subjects would be required to achieve Bonferroni-corrected p-value < 0.05 for ultra-rare truncating variants in KDR, and an even larger sample size of >1,600 TOF subjects would be required for FOXO1, WNT5A and ZFAND5. Identifying other, more homogenous subsets within the broader CHD spectrum may also be beneficial.